SA
NVO

SpiderRock Advisors’s Novo Nordisk NVO Stock Holding History

SpiderRock Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Hold
0
– -$3K – 282
2017
Q3 		– Hold
0
– – – 579
2017
Q2 		– Hold
0
– -$18K – 1081
2017
Q1 		– Hold
0
– – – 675

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SpiderRock Advisors's NVO Position: Q3 2024 in Review

SpiderRock Advisors reduced its Novo Nordisk (NVO) stake by 18% in Q3 2024, selling an estimated $363K and leaving 12,506 shares worth $1.49M. The position accounts for 0.02% of the portfolio, ranked #381.

SpiderRock Advisors first reported a position in NVO in Q1 2024 and has held it in 3 quarters since. The position peaked at $2.17M in Q2 2024. 1,784 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • SpiderRock Advisors held 12,506 shares of Novo Nordisk worth $1.49M as of Q3 2024.
  • SpiderRock Advisors sold 2,724 Novo Nordisk shares in Q3 2024, an estimated $363K.
  • Novo Nordisk made up 0.02% of SpiderRock Advisors's portfolio in Q3 2024, its #381 holding.
  • SpiderRock Advisors first reported a position in Novo Nordisk in Q1 2024 and has held it in 3 quarters since.
  • SpiderRock Advisors's Novo Nordisk position peaked at $2.17M in Q2 2024.
  • 1,784 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on SpiderRock Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.